Pulmonary Embolism Center

SYMPHONY-PE Analysis Shows Early Thrombectomy Linked to Better Outcomes

June 19, 2026—Imperative Care announced findings from a post hoc analysis of the SYMPHONY-PE trial that suggest that mechanical thrombectomy performed within 12 hours of diagnosis may be associated with greater hemodynamic and right ventricular recovery in patients with intermediate-risk pulmonary embolism (PE) compared with treatment performed later.

ENGULF Analysis Shows Reduced Blood Loss With E2’s Hēlo System in PE Procedures

May 4, 2026—A comparative analysis from the ENGULF trial demonstrated that using blood return during continuous aspiration thrombectomy dramatically reduced blood loss by 97%, while maintaining hemodynamic efficacy and improving procedural efficiency.

AHA/ACC Issue First Acute PE Guidelines With New Clinical Classification System

February 20, 2026—The American College of Cardiology (ACC)/American Heart Association (AHA) Joint Committee on Clinical Practice Guidelines and eight other professional societies released their first joint clinical practice guideline dedicated to the evaluation and management of acute pulmonary embolism (PE) in adults, introducing a new severity-based classification system and comprehensive recommendations spanning diagnosis, treatment, and follow-up care.

Penumbra’s CAVT Evaluated for Outcomes and Resource Utilization in Intermediate-Risk PE Patients

December 16, 2025—Penumbra announced the publication of a new study that showed that the use of the company’s computer-assisted vacuum thrombectomy (CAVT) technology for intermediate-risk pulmonary embolism (PE) may shorten length of hospital stay, reduce complications, and improve discharge outcomes without increasing mortality compared to other treatment modalities.

Thrombolex Bashir Catheter for Acute PE Studied in Interim Analysis of RAPID-PE

October 28, 2025—Thrombolex, Inc. announced findings from a prespecified interim analysis from the first 50 patients in the postmarket RAPID-PE study.

Penumbra’s CAVT With Anticoagulation Studied in STORM-PE

October 27, 2025—Penumbra, Inc. announced that the results of the STORM-PE randomized controlled trial showed that mechanical thrombectomy using the company’s computer assisted vacuum thrombectomy (CAVT) system with anticoagulation achieved superior reduction in right heart strain compared to anticoagulation therapy alone in patients with acute intermediate–high-risk pulmonary embolism (PE).

Argon Commences CLEAN-PE Study of Cleaner Pro Thrombectomy System

January 9, 2025—Argon Medical Devices announced the first patient enrollment in the CLEAN-PE study, which is estimated to enroll > 100 patients at hospitals across the United States.

Liquet Medical’s Versus Catheter Receives FDA Clearance

December 10, 2024—Liquet Medical Inc. announced it has received FDA 510(k) clearance for its Versus catheter for the treatment of pulmonary artery blood clots.

PEERLESS RCT Compares Large-Bore Mechanical Thrombectomy to CDT for Intermediate-Risk PE

October 29, 2024—Findings were presented from the international PEERLESS randomized controlled trial comparing patient outcomes after treatment with large-bore mechanical thrombectomy (LBMT) versus catheter-directed thrombolysis (CDT) for intermediate-risk pulmonary embolism (PE).

Endovascular Engineering Helo Thrombectomy System for Acute PE Evaluated in ENGULF Trial

May 3, 2024—Late-breaking data from the ENGULF trial showed that the dual-action Helo pulmonary embolism (PE) thrombectomy system (Endovascular Engineering [E2]) was effective and safe in treating acute PE.

The PERT Consortium Launches Pilot Program for Regional and Comprehensive PE Centers of Excellence

April 26, 2024—The PERT Consortium, a multidisciplinary, global, nonprofit organization dedicated to the care of pulmonary embolism (PE) patients, announced the launch of its Regional and Comprehensive PE Centers of Excellence pilot program.

Penumbra Lightning Flash 2.0 CAVT System Cleared by FDA and Launched

April 23, 2024—Penumbra, Inc. announced the FDA clearance and launch of Lightning Flash 2.0, the company’s next-generation computer assisted vacuum thrombectomy (CAVT) system for removal of venous thrombus and treatment of pulmonary emboli.

Thrombolex RESCUE II Study Begins Patient Enrollment

January 22, 2024—Thrombolex, Inc. announced the enrollment of the first patient in the RESCUE II study using the company’s Bashir endovascular catheter for the treatment of acute intermediate-risk pulmonary embolism (PE).

Study Uses PERT Consortium Registry Data to Examine Practice Patterns and Outcomes in High-Risk Pulmonary Embolism

January 17, 2024—In a retrospective analysis using data from the PERT Consortium registry, Kobayashi et al found high rates of in-hospital mortality and major bleeding in patients with high-risk pulmonary embolism (PE) as compared with intermediate-risk PE.

Endovascular Engineering’s Helo Thrombectomy System Receives IDE Approval for ENGULF Pivotal Trial to Treat PE

January 11, 2024—Endovascular Engineering (E2), a developer of clot removal technologies for venous thromboembolism, announced FDA approval for an investigational device exemption (IDE) for the ENGULF United States pivotal trial.

Study Evaluates Outcomes of Catheter-Based Therapy for Patients With Cancer and Intermediate- or High-Risk Pulmonary Embolism

January 11, 2024—A study published online in Catheterization and Cardiovascular Interventions by Leiva et al evaluating outcomes of patients with cancer hospitalized with intermediate- or high-risk pulmonary embolism (PE) found a lower risk of in-hospital death or cardiac arrest and a higher risk of major bleeding after treatment with catheter-based therapies (CBT) as compared with no CBT.

Inari PEERLESS II RCT Will Compare FlowTriever Versus Anticoagulation in PE Patients

May 22, 2023—Inari Medical, Inc. announced the planned enrollment of PEERLESS II, the company’s third randomized controlled trial (RCT) in venous thromboembolism (VTE).

FLASH All-Comers Registry Evaluates Inari’s FlowTriever Mechanical Thrombectomy Device for PE

May 19, 2023—The Society for Cardiovascular Angiography & Interventions (SCAI) announced that 6-month outcomes from FLASH showed that patients with pulmonary embolism (PE) who were treated with mechanical thrombectomy showed significant improvement in symptoms, quality of life, and cardiac functions.